Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Classical hematology 1

Conditions

Colorectal Neoplasms 4Stomach Neoplasms 2Rectal Neoplasms 2Pancreatic Neoplasms 2Esophageal Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Prostatic Neoplasms 1Ovarian Neoplasms 1Neutropenia 1Neoplasms 1Melanoma 1Head and Neck Neoplasms 1Fever 1Febrile Neutropenia 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Renal Cell 1Breast Neoplasms 1Adenocarcinoma Of Esophagus 1Adenocarcinoma 1

Interventions

Fluorouracil 219Leucovorin 202Oxaliplatin 192Irinotecan 150Bevacizumab 110Capecitabine 94Cetuximab 90Folfox protocol 54Chemotherapy, Adjuvant 36Panitumumab 30Colonoscopy 30pembrolizumab 23Drug Therapy 23Nivolumab 22Magnetic Resonance Spectroscopy 22Gemcitabine 21Blood Specimen Collection 20Radiotherapy 19Floxuridine 19Biopsy 19Neoadjuvant Therapy 18Laparoscopy 18IFL protocol 18Early Intervention, Educational 18Celecoxib 18Surveys and Questionnaires 17Surgical Procedures, Operative 16Immunohistochemistry 16Exercise 16trifluridine tipiracil drug combination 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Colonic Neoplasms × pegfilgrastim × Gastrointestinal × Clear all
NCT00094809 2018-10-17

Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer

Amgen

Phase 2 Completed
252 enrolled 19 charts
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00911170 2017-12-29

PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study

Amgen

Phase 3 Completed
847 enrolled 21 charts
Classical hematologyGastrointestinal

Colonic Neoplasms, Fever, Neoplasms, Neutropenia, Rectal Neoplasms, Colorectal Neoplasms, Febrile Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡